nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

20.06.2022 | main topic

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis

Immunotherapy with rituximab, ocrelizumab, and ofatumumab

verfasst von: Arkady Ovchinnikov, Dr.med. Oliver Findling

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2022

Einloggen, um Zugang zu erhalten

Summary

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration of brain tissue. For a long time, research focused on T cells as the primary mechanism of disease. Driven by reports on the clinical results of B cell-depleting therapies, this therapeutic approach has come into focus in the last decade, and new highly effective treatments have been developed and are now complementing the therapeutic landscape. This review provides an overview of the development of B cell-depleting therapies and shows the advantages and disadvantages of current developments. In addition, we discuss basic considerations for CD20-depleted MS patients in the face of the COVID-19 pandemic.

Vorheriger Artikel Experimental laboratory biomarkers in multiple sclerosis

Nächster Artikel Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21.CrossRefPubMedPubMedCentral

Dargahi N, Katsura M, Tselios T, Androutsou ME, Courten M de, Matsoukas J, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7):78. https://doi.org/10.3390/brainsci7070078.CrossRefPubMedCentral

Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8.CrossRefPubMedPubMedCentral

Murphy K, Travers P, Walport M. Janeway’s immunobiology. 3rd ed. New York: Garland Science; 2008.

Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663–4.CrossRefPubMed

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580–6.CrossRefPubMed

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.CrossRefPubMedPubMedCentral

Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Rheumatol Clin. 2011;7(5):314–22.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400.CrossRefPubMed

10.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.CrossRefPubMed

11.

de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to Rituximab. Neurology. 2016;87(2):141–7.CrossRefPubMed

12.

Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011. https://doi.org/10.1016/S0140-6736(11)61649-8CrossRef

13.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34.CrossRefPubMed

14.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20.CrossRefPubMed

15.

Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573–81.CrossRefPubMed

16.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90(20):e1805–e14.CrossRefPubMedPubMedCentral

17.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–57.CrossRefPubMed

18.

Berntsson SG, Kristoffersson A, Bostrom I, Feresiadou A, Burman J, Landtblom AM. Rapidly increasing off-label use of Rituximab in multiple sclerosis in Sweden—Outlier or predecessor? Acta Neurol Scand. 2018;138(4):327–31.CrossRefPubMed

19.

Salzer J, Svenningsson R, Alpine P, Novakova L, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–81.CrossRefPubMedPubMedCentral

20.

Gold R (federführend für das Redaktionskomitee). DGN/KKNMS Leitlinie zur Diagnose und Therapie der MS. Online-Version, Stand: 13.08.2014. http://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2016/02/dgn-kknms_ms-ll_20140813.pdf. Accessed 03.06.2022.

21.

Gingele S, Jacobus TL, Konen FF, Hummert MW, Suhs KW, Schwenkenbecher P, et al. Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients. Cells. 2018;8(1):12. https://doi.org/10.3390/cells8010012.CrossRefPubMedCentral

22.

Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of Rituximab. Rev Med Virol. 2019;29(6):e2077.CrossRefPubMed

23.

Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738–44.CrossRefPubMedPubMedCentral

24.

Achtnichts L, Jakob B, Oberle M, Nedeltchev K, Fux CA, Sellner J, et al. Humoral immune response after the third SARS-CoV‑2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines (Basel). 2021;9(12):1470. https://doi.org/10.3390/vaccines9121470.CrossRef

25.

Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1035. https://doi.org/10.1212/NXI.0000000000001035.

26.

Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Baroni A, Lapucci C, et al. Effect of SARS-CoV‑2 mRNA vaccination in MS patients treated with disease-modifying therapies. eBioMedicine. 2021;72:103581.CrossRefPubMedPubMedCentral

27.

Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-coV‑2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021;78(12):1529–31.CrossRefPubMedPubMedCentral

28.

Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal antibodies for multiple sclerosis: an update. BioDrugs. 2019;33(1):61–78.CrossRefPubMed

29.

Interim Results of an Open-Label Study to Assess Humoral Immune Response to COVID 19 mRNA Vaccine in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. ClinicalTrials.gov. Identifier: NCT04878211. https://clinicaltrials.gov/ct2/show/NCT04878211.

30.

Cross AH, Delgado S, Habeck M, Davydovskaya M, Ward BJ, Cree BAC, et al. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with Ofatumumab. Neurol Ther. 2022;11(2):741-758. https://doi.org/10.1007/s40120-022-00341-z.CrossRefPubMedPubMedCentral

31.

Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–9.CrossRefPubMed

32.

Achtnichts L, Ovchinnikov A, Jakob B, Oberle M, Nedeltchev K, Fux CA, et al. SARS-coV‑2 mRNA vaccination in people with multiple sclerosis treated with Fingolimod: protective humoral immune responses may develop after the preferred third shot. Vaccines (Basel). 2022;10(2):341. https://doi.org/10.3390/vaccines10020341.CrossRef

33.

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835. https://doi.org/10.1177/17562864211012835.CrossRefPubMedPubMedCentral

34.

Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–e85.CrossRefPubMedPubMedCentral

35.

Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137–52.CrossRefPubMed

36.

Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236–43.CrossRefPubMed

37.

Cree BA. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis—Commentary. Mult Scler. 2018;24(9):1161–2.CrossRefPubMed

Titel: An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis
Immunotherapy with rituximab, ocrelizumab, and ofatumumab
verfasst von: Arkady Ovchinnikov
Dr.med. Oliver Findling
Publikationsdatum: 20.06.2022
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 15-16/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-022-00939-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2022

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity

Neuer Masterstudiengang: Multiple Sklerose Management

Multiple sclerosis at the crossroads of scientific evidence and clinical translation

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever